04:27 AM EDT, 07/30/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) said late Monday the US Food and Drug Administration has approved its potassium phosphates in 0.9% sodium chloride injection intravenous ready-to-use bags.

The company said the sterile presentation simplifies the compounding process for clinicians, reducing the steps usually required for administering the product.

The product is indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kilograms or more when other therapies are not possible or insufficient, Amneal said.

The company plans to launch the product in Q3.

Price: 7.43, Change: +0.09, Percent Change: +1.23